GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Ovid Therapeutics Inc.
Ovid Therapeutics is a biotech company focused on treating rare neurological diseases. Its stock price reflects its drug development and licensing strategy. The chart is driven by clinical data and deal updates.
Share prices of companies in the market segment - Neuro
Ovid Therapeutics is a biopharmaceutical company focused on developing drugs for rare neurological diseases, often in collaboration with major pharmaceutical companies. We've classified it in the "Neuro" segment, which encompasses developers of drugs for the central nervous system. The chart below illustrates the overall dynamics of this complex and risky biotech sector.
Broad Market Index - GURU.Markets
Ovid Therapeutics is a biotech company specializing in developing drugs to treat rare neurological diseases. As an innovator in this field, it is included in our GURU.Markets index. The chart below shows the overall market trend. See how Ovid shares compare to sentiment in the biotech sector.
Change in the price of a company, segment, and market as a whole per day
OVID - Daily change in the company's share price Ovid Therapeutics Inc.
Ovid Therapeutics Inc.'s daily stock price fluctuations reflect the extreme volatility inherent in biotech companies working in the field of rare neurological diseases. This metric is a measure of sensitivity to clinical trial data.
Daily change in the price of a set of shares in a market segment - Neuro
Ovid Therapeutics Inc.'s daily stock price fluctuations reflect the extreme volatility inherent in biotech companies working in the field of rare neurological diseases. This metric is a measure of sensitivity to clinical trial data.
Daily change in the price of a broad market stock, index - GURU.Markets
Ovid Therapeutics is a biotech company specializing in the treatment of rare neurological diseases. Its shares move in sync with news about clinical trials. This high, event-driven volatility feeds into the overall market flow.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Ovid Therapeutics Inc.
Ovid Therapeutics Inc.'s year-over-year performance tells the story of its strategic pivot following the failure of its core program. Its market cap change over the past 12 months reflects its focus on developing drugs for rare neurological diseases and investors' confidence in the success of its new candidates and scientific platform.
Annual dynamics of market capitalization of the market segment - Neuro
Ovid Therapeutics Inc. is a biotech company focused on developing drugs for the treatment of rare neurological diseases. Its stock performance is entirely dependent on clinical trial results. The chart reflects the high risks and potential for breakthroughs typical of the biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Ovid Therapeutics is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Ovid Therapeutics Inc.
Ovid Therapeutics is a biotech company focused on rare neurological diseases. Its monthly performance is entirely dependent on developments in its clinical programs and partnerships. News of trial results and receipt of royalties under licensing agreements are the primary drivers of its value.
Monthly dynamics of market capitalization of the market segment - Neuro
Ovid Therapeutics Inc. is a biopharmaceutical company focused on developing drugs for rare neurological diseases. Its sector dynamics, shown in the chart, reflect the risks of R&D. Against this backdrop, one can assess how its strategy, based on a deep understanding of the genetics of rare epilepsies and other disorders, advances its candidates through clinical trials.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Ovid Therapeutics is a biopharmaceutical company focused on rare neurological diseases. Its shares are buoyed by anticipation of clinical trial results. The chart shows that the company's monthly share price fluctuations are unrelated to overall market trends, but rather reflect scientific news.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Ovid Therapeutics Inc.
Ovid Therapeutics, a biotech focused on rare neurological diseases, is experiencing high volatility. Weekly stock performance is driven by news of clinical trials and partnerships with major pharmaceutical companies, reflecting the risks and hopes in this complex field.
Weekly dynamics of market capitalization of the market segment - Neuro
Ovid Therapeutics focuses on developing drugs for rare neurological diseases, a field with high risks and potential rewards. The chart shows how the market reacts to the company's news compared to general trends in neuroscience, reflecting investor confidence in its scientific research.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Ovid Therapeutics is a biotech company focused on neuroscience. Its shares exist in a world of their own, where research data is king. The chart clearly demonstrates that OVID's performance is largely uncorrelated with the market, moving based on its own unique news.
Market capitalization of the company, segment and market as a whole
OVID - Market capitalization of the company Ovid Therapeutics Inc.
The Ovid Therapeutics chart is a financial map of the drug discovery process for rare neurological diseases. The company's market cap reflects its strategy of partnering with big pharma and its focus on diseases with high unmet need. Its dynamics are a barometer of progress in its clinical programs and confidence in its scientific approach.
OVID - Share of the company's market capitalization Ovid Therapeutics Inc. within the market segment - Neuro
Ovid Therapeutics' market share in the neuroscience sector reflects its focus on treating rare neurological diseases. Its market share is based on the potential of its pipeline of developments targeting the genetic causes of epilepsy and other disorders, making it a significant player in this complex field.
Market capitalization of the market segment - Neuro
Ovid Therapeutics is a biotech company specializing in rare neurological diseases. The chart below shows the overall market capitalization of this complex sector. Its performance is a barometer of investor hopes that science will find the keys to curing brain diseases.
Market capitalization of all companies included in a broad market index - GURU.Markets
Ovid Therapeutics is a biopharmaceutical company focused on developing treatments for rare neurological diseases. Its market capitalization reflects the potential of its scientific developments. The chart below shows the economic weight of companies at the forefront of neuroscience.
Book value capitalization of the company, segment and market as a whole
OVID - Book value capitalization of the company Ovid Therapeutics Inc.
For Ovid Therapeutics, a biopharmaceutical company, book value represents its R&D capital. The chart below shows its financial resources for developing drugs for rare neurological diseases. Its level is an indicator of its ability to fund its research programs.
OVID - Share of the company's book capitalization Ovid Therapeutics Inc. within the market segment - Neuro
Ovid Therapeutics is a biotech company focused on rare neurological diseases. Its primary asset is a portfolio of promising molecules. Its tangible asset share will be minimal, as is typical for R&D companies whose value lies in their intellectual property.
Market segment balance sheet capitalization - Neuro
Ovid Therapeutics is a biotech company focused on rare neurological diseases. Its value lies in clinical research, not manufacturing. This is a "light" model. The chart below shows the total material "weight" of the entire biopharmaceutical industry.
Book value of all companies included in the broad market index - GURU.Markets
Ovid Therapeutics' assets are focused on developing drugs for rare neurological diseases. Their book value reflects their strategy of acquiring and developing promising assets in orphan medicine, aimed at helping small patient groups.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Ovid Therapeutics Inc.
Ovid Therapeutics focuses on developing drugs for rare neurological diseases. Its balance sheet consists of cash and royalty rights from previously developed drugs. Its market capitalization reflects both these future cash flows and the potential of its own pipeline. The chart shows how the market values this hybrid biotech model.
Market to book capitalization ratio in a market segment - Neuro
Ovid Therapeutics is a biopharmaceutical company focused on treating rare neurological diseases. Its value is determined by its scientific pipeline. The chart shows the significant premium investors are paying for the potential of its drugs, which is typical for clinical-stage companies.
Market to book capitalization ratio for the market as a whole
Ovid Therapeutics is a biotech company specializing in developing drugs for rare neurological diseases. This chart shows how the market values a company focused on complex medical challenges. Its market capitalization is based on the potential of its scientific developments, representing a high-risk bet on future success in clinical trials.
Debts of the company, segment and market as a whole
OVID - Company debts Ovid Therapeutics Inc.
Ovid Therapeutics is a biopharmaceutical company focused on treating rare neurological diseases. Following its strategic shift, the company is managing its capital to fund remaining programs and seek new assets. This chart shows how Ovid is using its financial resources during the transition period.
Market segment debts - Neuro
Ovid Therapeutics is a biopharmaceutical company specializing in rare neurological diseases. Following recent strategic shifts, the company has focused on new programs. The chart shows common financial metrics for the biotech sector, which can be used to assess how Ovid is managing its capital during the transition period to fund promising areas.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Ovid Therapeutics Inc.
Ovid Therapeutics is a biotech company specializing in rare neurological diseases. Drug development in this field is associated with high risks and costs. This chart shows the company's reliance on debt financing to advance its clinical programs, a key indicator of its financial vulnerability.
Market segment debt to market segment book capitalization - Neuro
Developing drugs to treat rare neurological diseases, a focus of Ovid Therapeutics, requires deep scientific expertise and significant capital. This chart illustrates how the biotech sector finances such risky projects. It allows one to appreciate how Ovid's financial model, often working in partnerships, differs from other companies in this field.
Debt to book value of all companies in the market
Ovid Therapeutics focuses on treating rare neurological diseases. Biotech companies in the development stage often have negative cash flow and use debt to fund research. The chart shows how their financial strategy compares to the overall market.
P/E of the company, segment and market as a whole
P/E - Ovid Therapeutics Inc.
This chart shows the valuation of Ovid Therapeutics, a biopharmaceutical company focused on treating rare neurological diseases. For a clinical-stage company, its value is determined not by current profits, but by the potential of its scientific developments and partnerships with major pharmaceutical players.
P/E of the market segment - Neuro
This metric represents the average valuation for the biotech sector in which Ovid Therapeutics operates. In this industry, filled with research-stage companies, the average earnings estimate is often uninformative. However, it does reflect the overall level of investor optimism regarding treatments for rare neurological diseases.
P/E of the market as a whole
Ovid Therapeutics is a biotech company specializing in the treatment of rare neurological diseases. Its strategy includes both in-house development and partnerships with major companies. This chart shows the biotech sentiment. It helps understand how the market views Ovid's pipeline and its ability to bring orphan disease treatments to patients.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Ovid Therapeutics Inc.
Ovid Therapeutics is a biotech company specializing in drug development for rare neurological diseases. Its strategy includes both internal development and partnerships. The company's future depends on the success of its clinical programs. This chart shows how investors view its pipeline and its potential to address complex neurological challenges.
%20P%2FE%20Ovid%20Therapeutics%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Ovid-Therapeutics-Inc.&v=1772687047704 "Chart of the company's future (projected) P/E Ovid Therapeutics Inc.")
Future (projected) P/E of the market segment - Neuro
Ovid Therapeutics is a biotech company focused on developing drugs to treat rare neurological diseases. Following the failure of one of its key drugs, the company is reassessing its strategy. This chart reflects expectations for the biotech sector, helping to understand how the market views Ovid's ability to find new promising avenues.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Neuro&v=1772687047716 "Future (projected) P/E graph of the market segment - Neuro")
Future (projected) P/E of the market as a whole
Ovid Therapeutics is a biopharmaceutical company focused on developing drugs for rare neurological diseases. Their strategy includes partnerships and developing their own pipeline. This chart of general expectations illustrates investor sentiment toward biotech. Market optimism and risk appetite are essential to funding long-term and expensive research in this complex area of medicine.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772687047717 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Ovid Therapeutics Inc.
Ovid Therapeutics is a biotech company specializing in the treatment of rare neurological diseases. This chart shows the company's financial results after a strategic shift. Profits may come from royalties on previously developed drugs, while the company invests these funds in its new research pipeline.
Profit of companies in the market segment - Neuro
Basel Medical Group is likely a company in the medical services or equipment sector. Its profitability will depend on the specifics of its operations. This chart reflects general trends in healthcare, whether it's the stable demand for medical services or the need for continuous innovation in the equipment sector to maintain profitability.
Overall market profit
Ovid Therapeutics is a biotechnology company focused on developing drugs for the treatment of rare neurological diseases. Following its strategic shift, the company is leveraging its expertise to identify and develop promising assets. Its success depends on the correct selection of scientific directions and the results of future clinical trials.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Ovid Therapeutics Inc.
Ovid Therapeutics is a biotech company focused on developing drugs to treat rare neurological diseases. Its revenue forecast depends on the success of clinical trials and partnerships. This chart shows analyst expectations for its scientific developments and their potential to address the needs of patients with epilepsy and other disorders.
%20profit%20of%20the%20company%20Ovid%20Therapeutics%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Ovid-Therapeutics-Inc.&v=1772687047806 "Graph of future (projected) profit of the company Ovid Therapeutics Inc.")
Future (predicted) profit of companies in the market segment - Neuro
Ovid Therapeutics is a biotech company focused on developing drugs to treat rare neurological diseases, such as epileptic encephalopathies. This chart shows profitability projections for the biotech sector. It reflects the high hopes and significant risks associated with finding treatments for the most complex and rare brain diseases.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Neuro&v=1772687047808 "Graph of future (predicted) profits of companies in a market segment - Neuro")
Future (predicted) profit of the market as a whole
Ovid Therapeutics is a biotech company specializing in rare neurological diseases. Its success is determined by scientific advancements, not economic cycles. However, the overall corporate earnings forecasts presented here influence investors' risk appetite and how they evaluate biotech companies when raising capital or entering into partnerships.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772687047808 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Ovid Therapeutics Inc.
Ovid Therapeutics is a biotech company specializing in the treatment of rare neurological diseases. It operates using a model in which some of its development is conducted in partnership with large companies. The chart reflects investor valuations of its pipeline of drug candidates and the potential value of future royalties and license fees.
P/S market segment - Neuro
Ovid Therapeutics Inc. is a biopharmaceutical company specializing in the development of drugs for the treatment of rare neurological diseases. The company focuses on genetically determined brain disorders. This chart shows the average valuation for the sector, allowing one to assess how the market perceives the revenue potential of Ovid's developments in the complex field of neuroscience.
P/S of the market as a whole
Ovid Therapeutics is a biopharmaceutical company focused on developing drugs for rare neurological diseases. The company is working on breakthrough therapies. This chart, reflecting the average estimated real revenue, clearly highlights how biotech investments are betting on scientific breakthroughs in neuroscience.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Ovid Therapeutics Inc.
Ovid Therapeutics is a biopharmaceutical company focused on developing drugs for rare neurological diseases. This chart shows how investors assess the future potential of its pipeline. This assessment is based on expectations for successful clinical trials, which could lead to the development of new treatments.
%20P%2FS%20Ovid%20Therapeutics%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Ovid-Therapeutics-Inc.&v=1772687047835 "The graph of the company's future (projected) P/S Ovid Therapeutics Inc.")
Future (projected) P/S of the market segment - Neuro
Ovid Therapeutics is a biotech company developing drugs to treat rare neurological diseases such as Angelman syndrome and other epilepsies. The chart shows how investors estimate Ovid's future sales, reflecting the potential of its developments for patients with limited or no treatment options.
%20P%2FS%20market%20segment%20graph%20-%20Neuro&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Neuro&v=1772687047847 "Future (projected) P/S market segment graph - Neuro")
Future (projected) P/S of the market as a whole
Investor optimism about future earnings depends on progress in treating rare neurological diseases. Ovid Therapeutics is focused on developing drugs for conditions such as Angelman syndrome. Their work, while high-risk, offers hope to patients and their families and demonstrates that biotechnology is not leaving even the rarest diseases behind.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772687047861 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Ovid Therapeutics Inc.
Ovid Therapeutics is a biopharmaceutical company focused on developing drugs for rare neurological diseases. Currently, its revenue is generated not from sales, but from payments from partners under licensing agreements for the drugs it develops. This chart illustrates its partnership strategy for bringing drugs to market.
Sales of companies in the market segment - Neuro
Ovid Therapeutics is a biopharmaceutical company focused on developing drugs to treat rare neurological diseases, such as epileptic encephalopathies. This chart shows total revenue in the neurological pharmaceutical segment. It illustrates the importance and complexity of developing drugs for orphan diseases, where Ovid strives to help patients.
Overall market sales
Ovid Therapeutics is a biopharmaceutical company focused on developing drugs for the treatment of rare neurological diseases. Its strategy includes both internal development and partnerships. The company's future depends on the success of its clinical programs. This overall economic climate impacts the availability of capital for funding rare disease research.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Ovid Therapeutics Inc.
Ovid Therapeutics is a biotech company focused on developing drugs for rare neurological diseases. Its strategy includes both in-house development and partnerships. Its future depends on the success of clinical trials. The chart shows analysts' speculative forecasts, betting on a breakthrough in this complex area of medicine.
%20sales%20of%20the%20company%20Ovid%20Therapeutics%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Ovid-Therapeutics-Inc.&v=1772687047934 "Schedule of future (projected) sales of the company Ovid Therapeutics Inc.")
Future (projected) sales of companies in the market segment - Neuro
Ovid Therapeutics is a biopharmaceutical company focused on developing drugs to treat rare neurological diseases, such as epileptic encephalopathies. Its success depends on clinical trials. This chart reflects forecasts for the entire neurological pharmaceutical segment, showing analysts' overall expectations for the development of this medical field.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Neuro&v=1772687047966 "Schedule of future (projected) sales of companies in the market segment - Neuro")
Future (projected) sales of the market as a whole
Ovid Therapeutics is a biopharmaceutical company focused on treating rare neurological diseases. Its strategy includes both proprietary developments and partnerships. Success depends on clinical results. This overall economic activity schedule impacts the availability of capital for the biotech sector, which is necessary to finance long-term and risky programs.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772687047970 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Ovid Therapeutics Inc.
Ovid Therapeutics is a biotech company focused on rare neurological diseases. This metric reflects its financial strategy following its shift in focus. It shows how the company manages its resources, converting partnership revenue into the results needed to fund the development of new drug candidates.
Market segment marginality - Neuro
Ovid Therapeutics is a biotech company focused on developing drugs for the treatment of rare neurological diseases. Its financial performance reflects its focus on clinical trials. This chart provides insight into the company's operating model and cost structure compared to other neuroscience biotechs.
Market marginality as a whole
Ovid Therapeutics is a biopharmaceutical company focused on developing treatments for rare neurological diseases. Their approach is based on a deep understanding of the genetic basis of these diseases. Their success depends entirely on the results of clinical trials. This overall profitability curve does not affect their scientific activities.
Employees in the company, segment and market as a whole
Number of employees in the company Ovid Therapeutics Inc.
Ovid Therapeutics is a biotech company focused on developing drugs for rare neurological diseases. Its strategy emphasizes a small but highly effective team. This chart shows the dynamics of the team of scientists and clinicians working to advance its targeted therapeutic programs.
Share of the company's employees Ovid Therapeutics Inc. within the market segment - Neuro
Ovid Therapeutics focuses on developing drugs to treat rare neurological diseases. This chart shows the concentration of leading neurobiologists and geneticists. This percentage reflects the company's commitment to finding solutions for patients with poorly understood and severe central nervous system disorders.
Number of employees in the market segment - Neuro
Ovid Therapeutics Inc. is a biotechnology company focused on developing drugs to treat rare neurological diseases. This chart shows overall employment in the neurology sector. It illustrates the company's commitment to finding solutions for patients with severe diseases for which there are few or no treatment options.
Number of employees in the market as a whole
Ovid Therapeutics is a biotech company focused on developing drugs for the treatment of rare neurological diseases, particularly epilepsy. Working in this field requires deep scientific expertise. This graph illustrates the labor market, where science-intensive companies solving complex medical problems attract top scientists and clinicians, driving science forward.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Ovid Therapeutics Inc. (OVID)
Ovid Therapeutics Inc. is a biopharmaceutical company focused on developing drugs for rare neurological diseases. This chart is a prime example of biotech. The very high market capitalization per employee suggests that the market appreciates the potential of orphan drugs developed by a small scientific team.
%20of%20the%20company%20Ovid%20Therapeutics%20Inc.%20(OVID)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Ovid-Therapeutics-Inc.-OVID&v=1772687048107 "Chart of market capitalization per employee (in thousands of dollars) of the company Ovid Therapeutics Inc. (OVID)")
Market capitalization per employee (in thousands of dollars) in the market segment - Neuro
Ovid Therapeutics is a biotech company focused on rare neurological diseases. Like many companies in this field, its value is based on the potential of its drugs. This metric reflects the enormous value the market places on its research. A high valuation reflects investors' hopes for a breakthrough in the treatment of serious diseases.
%20by%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Neuro&v=1772687048108 "Market capitalization per employee (in thousands of dollars) by market segment - Neuro")
Market capitalization per employee (in thousands of dollars) for the overall market
Ovid Therapeutics Inc. is a biopharmaceutical company focused on rare neurological diseases. Its strategy includes both in-house development and partnerships. The company's employee valuation reflects the value of its scientific portfolio and the team's ability to advance complex programs through clinical trials.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772687048111 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Ovid Therapeutics Inc. (OVID)
Ovid Therapeutics is a biotech R&D company focused on rare neurological diseases (e.g., epilepsy). It's pure science. This metric demonstrates their capital burn rate—the net loss (clinical research expenses) per employee.
%20Chart%20Ovid%20Therapeutics%20Inc.%20(OVID)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Ovid-Therapeutics-Inc.-OVID&v=1772687048124 "Company Profit Per Employee (in thousands of dollars) Chart Ovid Therapeutics Inc. (OVID)")
Profit per employee (in thousands of dollars) in the market segment - Neuro
Ovid Therapeutics is a clinical-stage biotech focused on rare neurological diseases. Like most biotechs in R&D, this metric is currently negative. This chart provides a guide to the future. Success will depend on whether their scientific team can develop a drug that delivers profitability above the industry standard.
%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Neuro&v=1772687048127 "Chart of profit per employee (in thousands of dollars) in the market segment - Neuro")
Profit per employee (in thousands of dollars) for the market as a whole
Ovid Therapeutics (OVID) is a biotech company specializing in rare neurological diseases. They have transitioned from in-house R&D to a model where they own shares (royalties) in developments outsourced to other companies. This metric reflects the effectiveness of this "lightweight" model: few employees, but potential royalty income.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772687048137 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Ovid Therapeutics Inc. (OVID)
For Ovid Therapeutics, a company focused on treating rare neurological diseases, this graph reflects its research activities. Revenue per employee likely comes from partnerships, and future growth depends on the success of developing and commercializing new drugs.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Ovid-Therapeutics-Inc.-OVID&v=1772687048147 "Sales chart per company employee Ovid Therapeutics Inc. (OVID)")
Sales per employee in the market segment - Neuro
Ovid Therapeutics is a biopharmaceutical company focused on developing drugs for rare neurological diseases. This is R&D. This metric reflects the average revenue per employee in the segment. It allows us to assess how productive their scientific team is in this complex niche compared to other biotech companies working in the neuroscience field.
Sales per employee for the market as a whole
Ovid Therapeutics (OVID) is a biopharmaceutical company focused on treating rare neurological diseases. Currently, its staff consists primarily of scientists. This indicator for OVID is pending. It will only begin to grow if clinical trials are successful and either partner payments are received or marketing approval is obtained.
Short shares by company, segment and market as a whole
Shares shorted by company Ovid Therapeutics Inc. (OVID)
Ovid Therapeutics is a biotech company specializing in rare neurological diseases. Its lead program failed, and it now relies on royalties and early-stage development. This chart shows how many investors are betting that the company has no remaining promising assets and that its future royalties will not justify its current valuation.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Ovid-Therapeutics-Inc.-OVID&v=1772687048172 "Short Shares Chart for the Company Ovid Therapeutics Inc. (OVID)")
Shares shorted by market segment - Neuro
Ovid Therapeutics (OVID) is a biopharmaceutical company focused on developing treatments for rare neurological diseases such as epilepsy. This chart shows the overall short position in the neuroscience biotech sector. It reflects the high risk and failure rate associated with developing drugs to treat complex brain diseases.
Shares shorted by the overall market
Ovid Therapeutics is a clinical-stage biotech company focused on neuroscience. Its value reflects its hope for future success. When this overall pessimism indicator rises, investors are less inclined to hope. They are dumping unprofitable companies en masse, requiring refinancing.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Ovid Therapeutics Inc. (OVID)
This oscillator for Ovid Therapeutics is an indicator of hope in the treatment of rare neurological diseases (e.g., epilepsy). It's a biotech with binary bets. Positive trial data, especially for its key programs, triggers a surge of euphoria among investors, leading to overheating (above 70). A trial failure or an FDA request for new trials immediately collapses the oscillator (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Ovid-Therapeutics-Inc.-OVID&v=1772687048236 "RSI 14 indicator chart for the company's stock Ovid Therapeutics Inc. (OVID)")
RSI 14 Market Segment - Neuro
Ovid (OVID) is a "biotech" stock, a "hunter" for *rare* neurological diseases (Angelman syndrome). The "Neuro" (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of this entire segment. It's vital to understand: is OVID's growth due to its R&D or is *the entire* biotech sector simply overheated by expectations?
RSI 14 for the overall market
Ovid Therapeutics (OVID) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast OVID (Ovid Therapeutics Inc.)
Ovid Therapeutics is a biopharmaceutical company focused on developing drugs for rare neurological diseases (e.g., epilepsy). Its strategy is to discover and license promising assets. This chart shows the speculative average price target from analysts based on their assessment of the company's R&D portfolio.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-OVID-Ovid-Therapeutics-Inc.&v=1772687048284 "A chart showing analyst consensus forecasts for the expected stock price. OVID (Ovid Therapeutics Inc.)")
The difference between the consensus estimate and the actual stock price OVID (Ovid Therapeutics Inc.)
OVID - Ovid Therapeutics is a biotech company focused on developing drugs for rare neurological diseases (epileptics). This chart measures the gap between the current share price and the consensus target price. It shows how much confidence experts have in the company's R&D portfolio and scientific platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-OVID-Ovid-Therapeutics-Inc.&v=1772687048306 "A chart showing the difference between the consensus forecast and the actual stock price. OVID (Ovid Therapeutics Inc.)")
Analyst consensus forecast for stock prices by market segment - Neuro
Ovid Therapeutics (OVID) is a biotech company focused on developing drugs for rare neurological diseases (epileptic disorders). This chart shows analysts' overall expectations for the neuroscience sector. It reflects whether experts believe R&D in rare brain diseases is successful or whether they consider the sector too risky.
Analysts' consensus forecast for the overall market share price
Ovid Therapeutics is a biotech company specializing in developing drugs for rare neurological diseases (epileptics). This chart shows the overall risk appetite. For Ovid, a high-risk clinical-stage company, overall market optimism is critical to attracting the capital needed to fund long-term clinical trials.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Ovid Therapeutics Inc.
Ovid (OVID) is a portfolio company. They don't conduct their own R&D. They financed their R&D (at Takeda) and now own the rights (royalties and milestones) to a future epilepsy drug (Soticlestat). This chart is a binary bet. Its valuation is simply the market's belief that Takeda's clinical trials will be successful and Ovid will receive its paycheck.
AKIMA Market Segment Index - Neuro
Ovid Therapeutics is a biotech company specializing in developing drugs to treat rare neurological diseases, particularly epilepsy. This chart shows the average index for the neurosector. It provides investors with a benchmark for how Ovid's performance, which focuses on treating complex diseases, compares to the sector average.
The AKIM Index for the overall market
Ovid Therapeutics is a biopharmaceutical company specializing in rare neurological diseases (epilepsy). This chart, which reflects the market average, provides a macro backdrop. It helps assess how this scientific company, working to expand its pipeline, compares to overall economic trends in healthcare.
